| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
46.55(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $5.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
49,815 |
194,004 |
270,822 |
1,554,713 |
| Total Sell Value |
$38,529 |
$137,285 |
$342,023 |
$10,128,226 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
39 |
63 |
111 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brenner Malcolm |
Director |
– • – |
2021-02-18 |
4 |
AS |
$39.68 |
$275,366 |
I/I |
(6,757) |
1,000,521 |
|
-53% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-02-18 |
4 |
AS |
$39.20 |
$110,194 |
I/I |
(2,700) |
2,489,131 |
|
-53% |
|
| Vera Juan |
Director |
– • – |
2021-02-18 |
4 |
AS |
$39.48 |
$364,368 |
D/D |
(8,942) |
2,440,168 |
|
-53% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-17 |
4 |
AS |
$39.65 |
$602,521 |
D/D |
(15,196) |
490,134 |
|
-51% |
|
| Brenner Malcolm |
Director |
– • – |
2021-02-17 |
4 |
AS |
$38.66 |
$208,925 |
I/I |
(5,165) |
1,007,278 |
|
-51% |
|
| Vera Juan |
Director |
– • – |
2021-02-17 |
4 |
AS |
$38.71 |
$300,930 |
D/D |
(7,460) |
2,449,110 |
|
-51% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2021-02-17 |
4 |
AS |
$38.56 |
$93,763 |
D/D |
(2,320) |
66,306 |
|
-51% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-17 |
4 |
AS |
$38.42 |
$92,837 |
D/D |
(2,300) |
505,330 |
|
-51% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-02-17 |
4 |
AS |
$38.63 |
$92,468 |
I/I |
(2,286) |
2,491,831 |
|
-51% |
|
| Brenner Malcolm |
Director |
– • – |
2021-02-16 |
4 |
AS |
$41.75 |
$260,332 |
I/I |
(6,220) |
1,012,443 |
|
-49% |
|
| Vera Juan |
Director |
– • – |
2021-02-16 |
4 |
AS |
$41.79 |
$435,365 |
D/D |
(10,400) |
2,456,570 |
|
-49% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2021-02-16 |
4 |
AS |
$41.82 |
$127,816 |
D/D |
(3,050) |
68,626 |
|
-49% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-16 |
4 |
AS |
$41.76 |
$129,770 |
D/D |
(3,100) |
507,630 |
|
-49% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-02-16 |
4 |
AS |
$41.82 |
$127,733 |
I/I |
(3,050) |
2,494,117 |
|
-49% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-02 |
4 |
S |
$41.19 |
$2,014,603 |
D/D |
(48,910) |
510,730 |
|
49% |
|
| Melian Agustin |
Chief Medical Officer |
• – – |
2021-02-02 |
4 |
S |
$41.19 |
$2,259,230 |
D/D |
(54,849) |
520,266 |
|
49% |
|
| Hallal David |
Chief Executive Officer |
• • • |
2021-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
147,000 |
2,230,666 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
71,676 |
|
- |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
559,640 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
28,000 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
58,800 |
865,407 |
|
- |
|
| Atillasoy Ercem |
See Remarks |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
106,500 |
|
- |
|
| Melian Agustin |
Chief Medical Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
575,115 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
194,051 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2020-12-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
41,514 |
198,811 |
|
- |
|
288 Records found
|
|
Page 10 of 12 |
|
|
